Dr. Reddy’s to Announce Q3 FY26 Results and Host Earnings Call on January 21, 2026

Dr Reddy’s Laboratories ( (RDY) ) just unveiled an announcement.

On January 8, 2026, Dr. Reddy’s Laboratories announced that it will release its financial results for the quarter and nine months ended December 31, 2025 (Q3 FY26) on Wednesday, January 21, 2026, following a meeting of its board of directors. The company will also hold an earnings call on January 21, 2026 at 19:30 IST / 9:00 ET, with related materials including a press presentation, call audio and transcript to be made available via stock exchanges and the company’s website, providing investors and other stakeholders structured access to management’s discussion of recent financial performance.

The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

Dr Reddy’s Laboratories has a strong financial foundation and strategic growth initiatives, but faces challenges in the U.S. generics market and regulatory issues. The technical indicators suggest a bearish trend, and the valuation is reasonable but not compelling. The mixed sentiment from the earnings call reflects both opportunities and risks.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company headquartered in Hyderabad, Telangana. It operates in the generics and branded formulations space and is listed on the BSE, NSE, NYSE and NSE IFSC exchanges under the ticker DRREDDY/RDY, focusing on supplying medicines to regulated markets worldwide.

Average Trading Volume: 1,130,321

Technical Sentiment Signal: Hold

Current Market Cap: $11.53B

See more insights into RDY stock on TipRanks’ Stock Analysis page.